SWTX - SpringWorks Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
20.60
+1.33 (+6.90%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close19.27
Open19.47
Bid18.75 x 1800
Ask23.12 x 800
Day's Range19.17 - 20.81
52 Week Range17.66 - 28.62
Volume110,253
Avg. Volume342,723
Market Cap890.6M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-44.68
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.00
Trade prices are not sourced from all markets
  • Barrons.com

    Beacon Roofing, Sunrun, Marchex and Other 13D Filings

    Velan Capital and LTE Partners disclosed jointly on Sept. 19 that they added 658,061 shares to their stake in the cancer-focused biopharmaceutical at prices of $4.39 to $4.99 each from Sept. 3 to Sept. 9. The investors now hold a total of 10,161,733 shares, equal to about 11.5% of Progenics’ outstanding stock.

  • GlobeNewswire

    European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma

    SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the European Commission has granted Orphan Drug Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the treatment of soft tissue sarcoma. SpringWorks is currently enrolling patients in the Phase 3 DeFi trial of nirogacestat for the treatment of adult patients with progressing desmoid tumors, which are a type of soft-tissue tumors that are often treated by sarcoma specialists. Desmoid tumors are rare and often debilitating and disfiguring, and can aggressively invade surrounding healthy tissues and cause significant morbidities, including severe pain, internal bleeding, incapacitating loss of range of motion, and, in rare cases, death.1 It is estimated that 1,000 to 1,500 new desmoid tumor patients are diagnosed each year in the United States.2,3 There are currently no therapies approved by the U.S. Food and Drug Administration (FDA) for the treatment of desmoid tumors.

  • GlobeNewswire

    SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Shares

    STAMFORD, Conn., Sept. 17, 2019 -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for.

  • Cloudflare IPO Prices Above Range, Raises $525 Million
    Investor's Business Daily

    Cloudflare IPO Prices Above Range, Raises $525 Million

    Internet services company Cloudflare was set to begin trading Friday, after raising $525 million with an initial public offering that priced Thursday. Cloudflare offered 35 million shares.

  • GlobeNewswire

    SpringWorks Therapeutics Announces Pricing Of Initial Public Offering

    SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $18.00 per share. All of the shares are being offered by SpringWorks. The gross proceeds to SpringWorks from the offering, before deducting underwriting discounts and commissions and estimated offering expenses to be payable by SpringWorks, are expected to be $162 million.